Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|November 4, 2020

Sanofi Wins ISPE FOYA Overall Award

Sanofi’s Digitally Enabled Integrated Continuous Biomanufacturing Facility in Framingham, MA was named the Overall Award winner at the ISPE virtual annual meeting.

Sanofi was named the 2020 Facility of the Year Awards (FOYA) Overall Award winner by the International Society for Pharmaceutical Engineering (ISPE) at ISPE’s virtual awards banquet at the virtual annual meeting, the organization announced in a Nov. 3, 2020 press release. In April 2020, Sanofi received the Facility of the Future Category Award for its Digitally Enabled Integrated Continuous Biomanufacturing Facility in Framingham, MA. The facility’s continuous upstream and downstream processing design incorporates lean operations principles, and the facility design and the use of disposable process technology enables flexibility. Digital integration is extensive; the entire facility is run using a comprehensive suite of digital solutions.

According to the press release, achieving higher capacity in a smaller footprint provides the basis for an improved environmental footprint with:

  • More than 90% reduction in chemical usage per year
  • More than 90% reduction in water usage per year
  • 80% reduction in energy consumption and carbon dioxide emissions per year
  • More than 320 tons of waste saved from landfills every year.

Source: ISPE​


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.